Drug
Potassium Phosphate, Dibasic
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Contraindicated Product Administered | 67 | 156.1 | 200.9 | signal |
| 2 | Toxic Epidermal Necrolysis | 30 | 139.8 | 155.3 | signal |
| 3 | Sleep Disorder | 137 | 137.6 | 253.1 | signal |
| 4 | Treatment Failure | 116 | 99.2 | 161.5 | signal |
| 5 | Synovitis | 25 | 97.3 | 106.1 | signal |
| 6 | Infection | 138 | 67.2 | 123.9 | signal |
| 7 | Joint Stiffness | 25 | 66.9 | 72.9 | signal |
| 8 | Rheumatoid Arthritis | 106 | 65.8 | 101.4 | signal |
| 9 | Brain Injury | 9 | 62.9 | 64.9 | signal |
| 10 | Skin Lesion | 22 | 56.7 | 61.1 | signal |
| 11 | Drug Eruption | 13 | 51.8 | 54.1 | signal |
| 12 | Ventricular Fibrillation | 8 | 50.4 | 51.8 | signal |
| 13 | Product Use Issue | 127 | 47.7 | 82.1 | signal |
| 14 | Cytokine Release Syndrome | 12 | 44.2 | 46.0 | signal |
| 15 | Malignant Neoplasm Progression | 44 | 30.3 | 35.4 | signal |
| 16 | Herpes Zoster | 22 | 26.8 | 28.9 | signal |
| 17 | Myelodysplastic Syndrome | 5 | 24.2 | 24.6 | signal |